½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1462836

¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Á¦Ç°º°, µ¿·Â¿øº°, À¯Çüº°, »ç¿ë¼ºº°, Àü´Þ ºÎÀ§º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Needle-Free Injection Systems Market Size study & Forecast, by Product, By Source of Power, By Type, By Usability, By Site of Delivery, By Application, By End User, and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀåÀº 2022³â¿¡ ¾à 1¾ï 5,600¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2030³â¿¡´Â 20% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛÀº ÇǺο¡ ±¸¸ÛÀ» ¶Õ´Â ±âÁ¸ÀÇ ÁÖ»ç¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê°í ¾×ü Á¦Á¦, ¾à¹°, ¹é½ÅÀ» ȯÀÚ¿¡°Ô Àü´ÞÇϱâ À§ÇØ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä´Â ¹é½Å¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀ» ³ôÀÌ°í, ÁÖ»ç¹Ù´Ã°ú °ü·ÃµÈ À§ÇèÀ» ÁÙÀ̸ç, ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Ù´Â ÀåÁ¡À¸·Î ÀÎÇØ ÃÖ±Ù ¼ö³â°£ Å©°Ô Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ȯÀÚ ¼ö Áõ°¡¿Í Ä¡·á ÃËÁø, ¿¬±¸°³¹ß ºñ¿ë Áõ°¡, ´ç´¢º´ À¯º´·ü Áõ°¡ µî ÁÖ¿ä ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¾à¹°Àº ÁÖ»ç¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê°í °¡´ÉÇÑ ÇÑ Æí¸®ÇÏ°í °íÅë ¾øÀÌ Ã¼³»¿¡ Åõ¿©ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¹«¹Ù´ÃÁÖ»ç ½Ã½ºÅÛÀº ´Ù¾çÇÑ Áõ»óÀ» Ä¡·áÇϱâ À§ÇØ ¾à¹°Àü´Þ¿¡ äÅõǰí ÀÖ½À´Ï´Ù. °ñ´Ù°øÁõ ¹× ´ç´¢º´°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¹Ù´Ã ¾ø´Â ÁÖ»ç ½Ã½ºÅÛ ½ÃÀåÀÇ °¡Ä¡´Â ¿¹Ãø ±â°£ Áß »ó½ÂÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹¿¡¼­´Â 2022³â¿¡ 3,370¸¸ °Ç ÀÌ»óÀÇ ÀÔ¿øÀÌ ±â·ÏµÇ¾ú½À´Ï´Ù. ÃÖ±Ù ¼ö³â°£ º´¿ø ¼ö´Â °¨¼ÒÇÏ°í ÀÖÁö¸¸, ³ëÀÎ Àα¸´Â Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áö³­ 1³â°£ 1ȸ ÀÌ»ó ÀÔ¿øÇÑ °æÇèÀÌ ÀÖ´Â »ç¶÷ÀÇ ºñÀ²Àº ³²¼ºÀÇ °æ¿ì 4.8%ÀÎ ¹Ý¸é ¿©¼ºÀº ¾à 7.2%·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ 65¼¼ ÀÌ»óÀÇ 16.6%°¡ Áö³­ 1³â°£ ÀÔ¿øÇÑ °æÇèÀÌ ÀÖ´Â ¹Ý¸é, 18¼¼¿¡¼­ 44¼¼ »çÀÌ¿¡¼­´Â 6.6%¿¡ ºÒ°úÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¹Ì±¹ÀÇ Æò±Õ ÀÔ¿ø ±â°£Àº 5.7ÀÏÀÔ´Ï´Ù. ±×·¯³ª ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·°ú Á¤¸ÆÁÖ»ç ½Ã½ºÅÛ »ç¿ë Á¦ÇÑÀ¸·Î ÀÎÇØ 2023-2030³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â źźÇÑ ÀÇ·á ÀÎÇÁ¶ó, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ µÎµå·¯Áø Á¸Àç°¨, ¸¸¼ºÁúȯ »ç·Ê Áõ°¡, Áö¿ª³» ¿¬±¸ ³ë·ÂÀÇ ±ÞÁõ¿¡ ÈûÀÔ¾î ¼¼°è ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀåÀ» ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù.

ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº 2023-2030³â °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¹è°æ¿¡´Â ÀÎÁöµµ¸¦ ³ôÀ̱â À§ÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â, ¿¬±¸ È°µ¿ÀÇ È®´ë, ¹Ì°³Ã´ ½ÃÀåÀ¸·ÎÀÇ Á¢±Ù¼º, ´ë±Ô¸ð Àα¸ ±â¹Ý, Áö¿ª Àüü¿¡¼­ ¾çÁúÀÇ ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ¸ñÀûÀº ÃÖ±ÙÀÇ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ Á¤ÀÇÇÏ°í, ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. Á¶»ç ´ë»ó±¹³» »ê¾÷ÀÇ ÁúÀû¡¤¾çÀû Ãø¸é ¾çÃøÀ» Æ÷ÇÔ½ÃÅ°µµ·Ï ¼³°èµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ÇâÈÄ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦ µîÀÇ Áß¿äÇÑ Ãø¸é¿¡ °üÇÑ »ó¼¼ Á¤º¸µµ Á¦°øÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ ¹× Á¦Ç° Á¦°øÀÇ »ó¼¼ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇϱâ À§ÇÑ ¹Ì½ÃÀû ½ÃÀåÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÏ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
    • ¾÷°èÀÇ ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó³â
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå ¿ªÇÐ

  • ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ÃËÁø¿äÀÎ
      • ȯÀÚ ¼öÀÇ Áõ°¡¿Í Ä¡·áÀÇ ÃËÁø
      • ¿¬±¸°³¹ßºñÀÇ Áõ°¡
      • ´ç´¢º´ ȯÀÚÀÇ Áõ°¡
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
      • ¼÷·Ã Àü¹®°¡ÀÇ ºÎÁ·
      • Á¤¸Æ³» Åõ¿©¿¡¼­ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛÀÇ »ç¿ë Á¦ÇÑ
    • ½ÃÀå ±âȸ
      • ¹«Åë ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ°¡
      • ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÇ È®´ë

Á¦4Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five Forces ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19 ¿µÇ⠺м®
  • Æı«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð¡¤Á¦¾È

Á¦5Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : Á¦Ç°º°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : Á¦Ç°º°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : Á¦Ç°º° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ÃæÀü °¡´É
    • ÇÁ¸®Çʵå

Á¦6Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : µ¿·Â¿øº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : µ¿·Â¿øº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : µ¿·Â¿øº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • ´Ïµé ÇÁ¸® ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ½ºÇÁ¸µ½Ä ÀÎÁ§ÅÍ ½Ã½ºÅÛ
    • °¡½º ÃßÁø/°ø±â °­Á¦ ÀÎÁ§ÅÍ ½Ã½ºÅÛ

Á¦7Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : À¯Çüº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : À¯Çüº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå À¯Çüº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ¾×ü ±â¹Ý
    • »çÃâ/ÃàÀû ÁÖ»ç
    • ºÐ¸» ±â¹Ý

Á¦8Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : »ç¿ë¼ºº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : »ç¿ë¼º¡¤¼º´É º°-ÀáÀç ´É·Â ºÐ¼®
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : À¯Àúºô¸®Æ¼º° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ÀÏȸ¿ë
    • Àç»ç¿ë °¡´É

Á¦9Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : Àü´Þ ºÎÀ§º°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : Àü´Þ ºÎÀ§º°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : Åõ¿© ºÎÀ§º° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ÇÇÇÏ ÁÖ»ç±â
    • ±ÙÀ°³» ÁÖ»ç±â
    • Çdz» ÁÖ»ç±â

Á¦10Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : ¿ëµµº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : ¿ëµµº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ¹é½ÅÀü´Þ
    • Àν¶¸° Àü´Þ
    • ÅëÁõ °ü¸®
    • ±âŸ

Á¦11Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • º´¿ø°ú Áø·á¼Ò
    • ÀçÅÃÀÇ·á ÇöÀå
    • ¿¬±¸±â°ü
    • ±âŸ

Á¦12Àå ¼¼°èÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå, Áö¿ª ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
    • ¹Ì±¹
      • Á¦Ç° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • µ¿·Â¿øº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • À¯Çü ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • À¯Àúºô¸®Æ¼ ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ³³ÀÔ Àå¼Òº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ¾ÖÇø®ÄÉÀÌ¼Ç ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ÃÖÁ¾»ç¿ëÀÚÀÇ ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå ½º³À¼ô
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå ½º³À¼ô
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¹«¹Ù´Ã ÁÖ»ç ½Ã½ºÅÛ ½ÃÀå ½º³À¼ô
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦13Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • NuGen Medical Devices(Canada
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì¸¸)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • PharmaJet(U.S.)
    • Portal Instruments(U.S.)
    • Medical International Technology, Inc(U.S.)
    • Crossject SA(U.S.)
    • Antares Pharma(U.S.)
    • M(U.S.)
    • Injex Pharma AG(Germany)
    • NovaXS Biotech(U.S.)
    • INVIO Pharmaceutical Inc.(U.S.)

Á¦14Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»ç ÀüÁ¦Á¶°Ç
KSA 24.05.03

Global Needle-Free Injection Systems Market is valued approximately USD 156 million in 2022 and is anticipated to grow with a healthy growth rate of more than 20% over the forecast period 2023-2030. Needle-free injection systems are utilized for delivering liquid formulations, medications, and vaccines to patients without the use of traditional needles that pierce the skin. The demand for these systems has significantly risen in recent years due to their ability to enhance immune responses to vaccines, mitigate needle-related risks, and lower healthcare expenses. The market growth is driven by key factors such as growing Prevalence of Patients and Promote Treatment, rising expenditure for research and development, and rise in prevalence of diabetes.

Drugs are intended to be administered into the body most conveniently and painlessly possible, without the use of injection needles. Needle-free injection systems are employed for delivering medications to treat various conditions. It is projected that the value of the needle-free injection system market will rise over the forecasted period, driven by the growing prevalence of chronic diseases such as osteoporosis and diabetes. For instance, in 2022, the United States recorded over 33.7 million hospital admissions. Despite a decline in the number of hospitals in recent years, the country is witnessing a rise in its elderly population. As anticipated, the elderly constitute the largest demographic among hospital admissions in the U.S. Also, Hospital stays are more prevalent among females than males, with approximately 7.2 percent of females reporting one or more hospital stays in the past year, compared to 4.8 percent of males. Additionally, 16.6 percent of individuals aged 65 years and older experienced hospitalization in the past year, in contrast to only 6.6 percent of those aged 18 to 44 years. On average, a hospital stay in the United States lasts for 5.7 days. However, the lack of skilled professionals and restricted use of needle-free injection systems for intravenous administration stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Needle-Free Injection Systems Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is leading the Global Needle-Free Injection Systems Market, supported by robust healthcare infrastructure, the prominent presence of key market players, escalating cases of chronic diseases, and a surge in research endeavors within the region.

Meanwhile, the Asia-Pacific region is expected to be the fastest growing region from 2023 to 2030. This growth can be attributed to increased government initiatives aimed at raising awareness, expanding research activities, access to vast untapped markets, a large population base, and growing demand for quality healthcare services across the region.

Major market player included in this report are:

  • NuGen Medical Devices (Canada)
  • PharmaJet (U.S.)
  • Portal Instruments (U.S.)
  • Medical International Technology, Inc (U.S.)
  • Crossject SA (U.S.)
  • Antares Pharma (U.S.)
  • 3M (U.S.)
  • Injex Pharma AG (Germany)
  • NovaXS Biotech (U.S.)
  • INVIO Pharmaceutical Inc. (U.S.)

Recent Developments in the Market:

  • In October 2022, Science - Link Trading, a company dedicated to facilitating the commercialization of emerging disruptive technologies, entered into a distributorship agreement with NuGen Medical Devices Inc., a trailblazer in needle-free medicine delivery. The agreement outlines the purchase of 34,000 InsuJet devices over a span of five years, along with additional accessories.
  • In June 2022, NovaXS Biotech unveiled the latest prototype of its innovative smart medical device for needle-free injectable therapy. Named Telosis, this patent-pending device from NovaXS delivers medication through a narrow stream in just 0.3 seconds, eliminating the need for needles. Furthermore, Telosis evaluates injection data to enable informed medical decisions.

Global Needle-Free Injection Systems Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Product, Source of Power, Type, Usability, Site of Delivery, Application, End-user, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

  • Fillable
  • Prefilled

By Source of Power:

  • Spring-based Injector Systems
  • Gas Propelled/Air Forced Injector Systems

By Type:

  • Liquid-based
  • Projectile/Depot-based
  • Powder-based

By Usability:

  • Disposable
  • Reusable

By Site of Delivery:

  • Subcutaneous Injectors
  • Intramuscular Injectors
  • Intradermal Injectors

By Application:

  • Vaccine Delivery
  • Insulin Delivery
  • Pain Management
  • Others

By End User:

  • Hospitals & Clinics
  • Home Care Settings
  • Research Laboratories
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

  • 1.1.Market Snapshot
  • 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Million)
    • 1.2.1.Needle-Free Injection Systems Market, by Region, 2020-2030 (USD Million)
    • 1.2.2.Needle-Free Injection Systems Market, by Product, 2020-2030 (USD Million)
    • 1.2.3.Needle-Free Injection Systems Market, by Source of Power, 2020-2030 (USD Million)
    • 1.2.4.Needle-Free Injection Systems Market, by Type, 2020-2030 (USD Million)
    • 1.2.5.Needle-Free Injection Systems Market, by Usability, 2020-2030 (USD Million)
    • 1.2.6.Needle-Free Injection Systems Market, by Site of Delivery, 2020-2030 (USD Million)
    • 1.2.7.Needle-Free Injection Systems Market, by Application, 2020-2030 (USD Million)
    • 1.2.8.Needle-Free Injection Systems Market, by End-user, 2020-2030 (USD Million)
  • 1.3.Key Trends
  • 1.4.Estimation Methodology
  • 1.5.Research Assumption

Chapter 2.Global Needle-Free Injection Systems Market Definition and Scope

  • 2.1.Objective of the Study
  • 2.2.Market Definition & Scope
    • 2.2.1.Industry Evolution
    • 2.2.2.Scope of the Study
  • 2.3.Years Considered for the Study
  • 2.4.Currency Conversion Rates

Chapter 3.Global Needle-Free Injection Systems Market Dynamics

  • 3.1.Needle-Free Injection Systems Market Impact Analysis (2020-2030)
    • 3.1.1.Market Drivers
      • 3.1.1.1.Growing Prevalence of Patients and Promote Treatment
      • 3.1.1.2.Rising expenditure for research and development
      • 3.1.1.3.Rise in prevalence of diabetes
    • 3.1.2.Market Challenges
      • 3.1.2.1.Lack of skilled professionals
      • 3.1.2.2.Restricted use of needle-free injection systems for intravenous administration
    • 3.1.3.Market Opportunities
      • 3.1.3.1.Increasing Demand for Painless Drug Delivery
      • 3.1.3.2.Expansion of Vaccination Programs

Chapter 4.Global Needle-Free Injection Systems Market Industry Analysis

  • 4.1.Porter's 5 Force Model
    • 4.1.1.Bargaining Power of Suppliers
    • 4.1.2.Bargaining Power of Buyers
    • 4.1.3.Threat of New Entrants
    • 4.1.4.Threat of Substitutes
    • 4.1.5.Competitive Rivalry
  • 4.2.Porter's 5 Force Impact Analysis
  • 4.3.PEST Analysis
    • 4.3.1.Political
    • 4.3.2.Economical
    • 4.3.3.Social
    • 4.3.4.Technological
    • 4.3.5.Environmental
    • 4.3.6.Legal
  • 4.4.Top investment opportunity
  • 4.5.Top winning strategies
  • 4.6.COVID-19 Impact Analysis
  • 4.7.Disruptive Trends
  • 4.8.Industry Expert Perspective
  • 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Needle-Free Injection Systems Market, by Product

  • 5.1.Market Snapshot
  • 5.2.Global Needle-Free Injection Systems Market by Product, Performance - Potential Analysis
  • 5.3.Global Needle-Free Injection Systems Market Estimates & Forecasts by Product 2020-2030 (USD Million)
  • 5.4.Needle-Free Injection Systems Market, Sub Segment Analysis
    • 5.4.1.Fillable
    • 5.4.2.Prefilled

Chapter 6.Global Needle-Free Injection Systems Market, by Source of Power

  • 6.1.Market Snapshot
  • 6.2.Global Needle-Free Injection Systems Market by Source of Power, Performance - Potential Analysis
  • 6.3.Global Needle-Free Injection Systems Market Estimates & Forecasts by Source of Power 2020-2030 (USD Million)
  • 6.4.Needle-Free Injection Systems Market, Sub Segment Analysis
    • 6.4.1.Spring-based Injector Systems
    • 6.4.2.Gas Propelled/Air Forced Injector Systems

Chapter 7.Global Needle-Free Injection Systems Market, by Type

  • 7.1.Market Snapshot
  • 7.2.Global Needle-Free Injection Systems Market by Type, Performance - Potential Analysis
  • 7.3.Global Needle-Free Injection Systems Market Estimates & Forecasts by Type 2020-2030 (USD Million)
  • 7.4.Needle-Free Injection Systems Market, Sub Segment Analysis
    • 7.4.1.Liquid-based
    • 7.4.2.Projectile/Depot-based
    • 7.4.3.Powder-based

Chapter 8.Global Needle-Free Injection Systems Market, by Usability

  • 8.1.Market Snapshot
  • 8.2.Global Needle-Free Injection Systems Market by Usability, Performance - Potential Analysis
  • 8.3.Global Needle-Free Injection Systems Market Estimates & Forecasts by Usability 2020-2030 (USD Million)
  • 8.4.Needle-Free Injection Systems Market, Sub Segment Analysis
    • 8.4.1.Disposable
    • 8.4.2.Reusable

Chapter 9.Global Needle-Free Injection Systems Market, by Site of Delivery

  • 9.1.Market Snapshot
  • 9.2.Global Needle-Free Injection Systems Market by Site of Delivery, Performance - Potential Analysis
  • 9.3.Global Needle-Free Injection Systems Market Estimates & Forecasts by Site of Delivery 2020-2030 (USD Million)
  • 9.4.Needle-Free Injection Systems Market, Sub Segment Analysis
    • 9.4.1. Subcutaneous Injectors
    • 9.4.2.Intramuscular Injectors
    • 9.4.3.Intradermal Injectors

Chapter 10.Global Needle-Free Injection Systems Market, by Application

  • 10.1.Market Snapshot
  • 10.2.Global Needle-Free Injection Systems Market by Application, Performance - Potential Analysis
  • 10.3.Global Needle-Free Injection Systems Market Estimates & Forecasts by Application 2020-2030 (USD Million)
  • 10.4.Needle-Free Injection Systems Market, Sub Segment Analysis
    • 10.4.1.Vaccine Delivery
    • 10.4.2.Insulin Delivery
    • 10.4.3.Pain Management
    • 10.4.4.Others

Chapter 11.Global Needle-Free Injection Systems Market, by End-user

  • 11.1.Market Snapshot
  • 11.2.Global Needle-Free Injection Systems Market by End-user, Performance - Potential Analysis
  • 11.3.Global Needle-Free Injection Systems Market Estimates & Forecasts by End-user 2020-2030 (USD Million)
  • 11.4.Needle-Free Injection Systems Market, Sub Segment Analysis
    • 11.4.1.Hospitals & Clinics
    • 11.4.2.Home Care Settings
    • 11.4.3.Research Laboratories
    • 11.4.4.Others

Chapter 12.Global Needle-Free Injection Systems Market, Regional Analysis

  • 12.1.Top Leading Countries
  • 12.2.Top Emerging Countries
  • 12.3.Needle-Free Injection Systems Market, Regional Market Snapshot
  • 12.4.North America Needle-Free Injection Systems Market
    • 12.4.1.U.S. Needle-Free Injection Systems Market
      • 12.4.1.1.Product breakdown estimates & forecasts, 2020-2030
      • 12.4.1.2.Source of Power breakdown estimates & forecasts, 2020-2030
      • 12.4.1.3.Type breakdown estimates & forecasts, 2020-2030
      • 12.4.1.4.Usability breakdown estimates & forecasts, 2020-2030
      • 12.4.1.5.Site of Delivery breakdown estimates & forecasts, 2020-2030
      • 12.4.1.6.Application breakdown estimates & forecasts, 2020-2030
      • 12.4.1.7.End-user breakdown estimates & forecasts, 2020-2030
    • 12.4.2.Canada Needle-Free Injection Systems Market
  • 12.5.Europe Needle-Free Injection Systems Market Snapshot
    • 12.5.1.U.K. Needle-Free Injection Systems Market
    • 12.5.2.Germany Needle-Free Injection Systems Market
    • 12.5.3.France Needle-Free Injection Systems Market
    • 12.5.4.Spain Needle-Free Injection Systems Market
    • 12.5.5.Italy Needle-Free Injection Systems Market
    • 12.5.6.Rest of Europe Needle-Free Injection Systems Market
  • 12.6.Asia-Pacific Needle-Free Injection Systems Market Snapshot
    • 12.6.1.China Needle-Free Injection Systems Market
    • 12.6.2.India Needle-Free Injection Systems Market
    • 12.6.3.Japan Needle-Free Injection Systems Market
    • 12.6.4.Australia Needle-Free Injection Systems Market
    • 12.6.5.South Korea Needle-Free Injection Systems Market
    • 12.6.6.Rest of Asia Pacific Needle-Free Injection Systems Market
  • 12.7.Latin America Needle-Free Injection Systems Market Snapshot
    • 12.7.1.Brazil Needle-Free Injection Systems Market
    • 12.7.2.Mexico Needle-Free Injection Systems Market
  • 12.8.Middle East & Africa Needle-Free Injection Systems Market
    • 12.8.1.Saudi Arabia Needle-Free Injection Systems Market
    • 12.8.2.South Africa Needle-Free Injection Systems Market
    • 12.8.3.Rest of Middle East & Africa Needle-Free Injection Systems Market

Chapter 13.Competitive Intelligence

  • 13.1.Key Company SWOT Analysis
  • 13.2.Top Market Strategies
  • 13.3.Company Profiles
    • 13.3.1. NuGen Medical Devices (Canada)
      • 13.3.1.1.Key Information
      • 13.3.1.2.Overview
      • 13.3.1.3.Financial (Subject to Data Availability)
      • 13.3.1.4.Product Summary
      • 13.3.1.5.Recent Developments
    • 13.3.2. PharmaJet (U.S.)
    • 13.3.3.Portal Instruments (U.S.)
    • 13.3.4.Medical International Technology, Inc (U.S.)
    • 13.3.5.Crossject SA (U.S.)
    • 13.3.6.Antares Pharma (U.S.)
    • 13.3.7.3M (U.S.)
    • 13.3.8.Injex Pharma AG (Germany)
    • 13.3.9.NovaXS Biotech (U.S.)
    • 13.3.10.INVIO Pharmaceutical Inc. (U.S.)

Chapter 14.Research Process

  • 14.1.Research Process
    • 14.1.1.Data Mining
    • 14.1.2.Analysis
    • 14.1.3.Market Estimation
    • 14.1.4.Validation
    • 14.1.5.Publishing
  • 14.2.Research Attributes
  • 14.3.Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦